Jumonji domain-containing protein 3 (JMJD3/KDM6B) demethylates lysine 27 on histone 
Introduction
The histone H3K27 demethylase jumonji domain-containing protein 3 (JMJD3 or KDM6B) is a molecular switch controlling cellular programs of immune activation, injury repair responses including regeneration, and cellular senescence (1) (2) (3) (4) (5) . JMJD3 exerts these actions through H3K27 demethylase activity and control of polycomb repressive complexes by removal of tri-and di-methyl groups, as well as by direct effects on chromatin organization (4) .
Cellular senescence is a program of irreversible growth arrest initiated by stress and dysfunction [a related phenomenon being oncogene-induced senescence (OIS)]. An important component of the cellular senescence program is the senescence-associated secretory phenotype (SASP), a group of secreted proteins that includes growth factors, inflammatory cytokines, and proteases (the senescence messaging secretome) (6, 7) .
Recent findings place JMJD3 central to emergence of the SASP, the consequences of which on surrounding tissues depend on context (8) . These may be positive (suppression of tumorigenesis, promotion of tissue repair and regeneration) or deleterious [induction of pro-inflammatory cells, stimulation of tumor progression, undermining of normal tissue homeostasis and repair (9) ]. Thus, while the biology of cancers (including glioma) involves aberrant genetic changes, there is accumulating evidence that inflammatory processes associated with aging (10, 11) , along with epigenetic modifications and chromatin remodeling, play key roles in the neoplastic process (12, 13) .
In the present study we examined JMJD3 expression in glioma cells and its relation to emergence of senescence-associated phenotypes. We observed that higher levels of stimulating secretion of the inflammatory cytokines and proteases of the SASP (1, 14, 15) and other mechanisms, may contribute to tumorigenesis and tumor progression (16, 17) .
We specifically relate these studies to treatment of glioma, the most common type of primary malignant brain tumor in adults (18) . Because of the invasive nature of glioma, traditional treatment options such as surgery, chemotherapy and radiation, are not curative, and survival averages only 2-3 years following initial diagnosis (19) . For well over the past decade, cell-based therapies to target otherwise inaccessible neoplastic and chronic diseases associated with inflammation have increasingly been pursued.
Prominent among them are neural stem cells (NSCs) and other stem cells that intrinsically home to sites of tumors and other inflammatory areas (20) . Many of the inflammatory cytokines and proteases of the SASP have also been linked to the homing of therapeutically-useful NSCs to tumor foci. Cell-based therapies targeting pathologies associated with inflammation such as cancer and ischemia are currently in clinical trials.
Our study is thus particularly relevant because it suggests that the intrinsic biology underlying secretion of these factors is an important component of therapeutic disease 
Materials and Methods

Microarray analysis of JMJD3 expression in patient cohorts
Tumor versus normal gene expression was calculated using 429 primary patient samples and 31 normal samples taken from combined Sun et al. (21) and Gravendeel et al. (22) data sets, and evaluated by 2-way ANOVA (to correct for differences in expression between cohorts) was used to compare data sets using Partek ® Genomics Suite TM (Partek, Inc., St. Louis, MO). Fold-change values were calculated based upon the leastsquares mean using Partek ® Genomics Suite TM . Prior to statistical analysis, data were normalized using robust multichip average (RMA) normalization (23) . The correlation between JMJD3 and IL6 comes from pre-processed expression data from Freije et al. (24) . Pearson correlation coefficient and p-value was calculated using the cor.test function in R (25) .
Cell culture
U251 and U87 human glioma cell lines (purchased from ATCC and a gift from Dr. Michael C. Jensen, CoH) and normal human astrocytes (NHA; T0250, purchased from Applied Biological Materials, Richmond, BC V6V 2G2, Canada) were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, and penicillin (100 units/ml)/streptomycin (100 µg/ml). Human fetal mesenchymal stem cells (MSCs) immortalized by transduction with human telomerase reverse transcriptase (26) were cultured in alpha-MEM (Invitrogen, 12571), 100 μM ascorbic acid (Sigma, A8960), 2 mM L-glutamine, 15% FBS, 1% Pen/Strep. All cell cultures were incubated in a humidified chamber containing 6% CO 2 at 37 o C.
RNA isolation, cDNA synthesis, and RT-qPCR
RNA was isolated using Trizol reagent (Invitrogen) according to the manufacturer's protocol. A total of 2 µg of RNA was used for cDNA synthesis using the BioRad cDNA 
DNA constructs and generation of stable cell lines
All plasmid DNA was prepared using a Qiagen Maxi kit. pMSCV-JMJD3mut and pMSCVJMJD3wt constructs were purchased from Addgene (Cambridge, MA). A vector control plasmid was generated by excising the JMJD3 sequence from pMSCV-JMJD3mut construct using the XhoI restriction enzyme (New England Biolabs, Inc., Ipswich, MA), followed by T-4 mediated (New England Biolabs) ligation of the vector backbone with itself.
U251 glioma cells were transfected with 4 µg of DNA using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) in accordance with the manufacturer's protocol. Seventy-two hours post-transfection, puromycin (1 µg/ml) was added to culture media to select for transfected cells. A monoclonal stably-transfected U251 cell line for each condition (vector, JMJD3mut, and JMJD3wt) was generated by limiting dilution. Puromycin (1 µg/ml) was added to the culture media during the maintenance of the stable cell lines. U87 glioma cells were transfected with DNA following identical procedures, except that Lipofectamine LTX with plus reagent (Invitrogen, Carlsbad, CA) was used in accordance with the manufacturer's protocol, and these cells were maintained as a batch culture polyclonal population.
Immunofluorescence and microscopy
Cells were grown on Lab-Tek II glass chamber slides (154526, Nunc, Rochester, NY), rinsed in PBS, fixed with 4% paraformaldehyde (PFA) for 10 min, rinsed in PBS, and permeabilized by incubation in PBS containing Triton X-100 (0.25% v/v; 10 min), and blocked using 5% bovine serum albumin. Samples were then incubated with primary and then secondary antibodies. Cell nuclei were stained using DAPI (0.1 µg ml -1 ) for 2 min before mounting (DAKO). All images were taken using a Nikon TE2000-U fluorescence microscope, Zeiss LSM 510 confocal microscope, or Zeiss AxioObserver fluorescence microscope, as indicated in the text. Quantitative determinations of immunofluorescence intensity for individual cells were made using CellProfiler (27) (www.cellprofiler.org) with DAPI fluorescence marking cells for subsequent measurements.
Immunoblotting
Protein lysates were made using RIPA buffer (Thermo Scientific) containing protease (cOmplete ULTRA Tablets Mini EASY pack; Roche Applied Bioscience, Indianapolis, IN) and phosphatase inhibitors (PhosSTOP tablets; Roche Applied Bioscience) per manufacturer's guidelines (1 tablet of each / 7 ml RIPA buffer). Protein concentrations were determined by bicinchoninic acid protein assay (Thermo Scientific) and then adjusted to equal concentrations using lysis buffer, followed by addition of lithium dodecylsulfate loading buffer and 2-mercaptoethanol. Lysates (20 µg) were electrophoresed in Novex 4-12% Tris-glycine pre-cast gels (Invitrogen) in MOPS running buffer. Gel contents were transferred to a PVDF membrane using a BioRad semi-dry transfer system. Membranes were blocked in 5% non-fat milk, followed by addition of Western blotting substrate reagent and were then imaged using X-ray film.
Antibodies and reagents
The following commercially available antibodies were used at the indicated 
Flow cytometry
Flow cytometry was performed using a Guava EasyCyte flow cytometer (Guava Biotechnologies, Hayward, CA) equipped with software functions for analyzing cell viability and cell size as previously described (28) . To measure cell viability, cells were trypsinized from a T175 flask and incubated with Guava ViaCount reagent. Cell viability was determined using the Guava ViaCount assay function. Data were analyzed and scatter plots prepared using Flowjo software (TreeStar; Ashland, OR). 
Detection of SA-β-gal activity
Cell proliferation assay
U251 cell lines were cultured in 6-well dishes, and viable cells were counted daily using a Guava EasyCyte flow cytometer (Guava Biotechnologies) over seven days. 
Electron microscopy
JMJD3 inhibition
JMJD3 inhibitor GSK-J4 (30) was purchased from Tocris (4594; Bristol, UK).
U251.JMJD3wt cells were treated with 20 µM GSK-J4 for 3 days, added every 24 hours along with fresh media.
Chromatin immunoprecipitation assay (ChIP)
ChIP was performed using ChIP-IT Express Kit (102026, Active Motif, Carlsbad, CA) according to the manufacturer's protocol. Cells were grown in 10 cm dishes to 80% confluence and fixed by adding 260 μl of 37% formaldehyde directly to 10 ml of culture media covering the cells. Fixation was at room temperature for 2 min for histone ChIP assay or 10 min for H3K27me3 ChIP assay. Chromatin samples were prepared by sonication using a Misonex Sonicator 3000 for a total of 4 cycles; 40% power output for 10 s. Sheared chromatin was incubated with rabbit polyclonal antibodies and then precipitated using magnetic Protein G-coupled beads. DNA was purified using the 
RNA-seq data analysis
Reads were aligned to the human genome (build hg19) using TopHat (31) . Reads Per Kilobase per Million (RPKM) mapped reads (32) were calculated for RefSeq (33) transcripts using an expectation-maximization algorithm in Partek 
Cell invasion assay
In vitro cell invasion assays were performed using BD BioCoat™ Matrigel™ Invasion 
Boyden chamber cell migration assay
The Boyden chamber cell migration assay was performed as previously described (37) .
Briefly, HB1.F3.CD NSCs or MSCs were resuspended in 5% bovine serum albumin (BSA) and added to the top chambers of 8 µm-pore Millicell cell culture inserts (Millipore, P18P01250). As a chemoattractant, serum-free conditioned media was harvested from 
Statistical analysis
Student's t-test was performed using Microsoft Excel. Two-tailed p values are reported.
Statistical significance was set at: *p <0.05; ** p <0.01; *** p <0.001. 
Results
JMJD3 expression in patient samples and glioma cell lines
To examine whether JMJD3 is over-expressed at significant levels in patient glioma samples, we first performed analysis for JMJD3 expression using published microarray data available online (22, 38) . In patient samples we observed 1.37-fold up-regulation ; r = 0.41)
We then examined endogenous JMJD3 expression in normal human astrocytes and two human glioma cell lines (U251 and U87) by immunofluorescence. Images are presented in Figure 1C , and quantitative summaries of cell JMJD3 immunoreactivity in Figure 1D1 and 1D2. JMJD3 was not detected in normal human astrocytes, expressed at low levels in parental U251 glioma cells, and at relatively higher levels in parental U87 glioma cells and in U251 cells over expressing JMJD3 (U251.JMJD3wt).
Taken together, these observations suggest association of JMJD3 expression with brain tumor cells, as indicated by glioma patient samples and glioma cell lines.
Association of JMJD3 with markers of cellular senescence
We developed genetically-modified U251 and U87 lines as tools to examine the relationships between JMJD3 expression and display of a series of biomarkers characteristic of senescent cells (40) : cell morphology, senescence-associated-β-galactosidase (SA β-gal) activity, proliferation, chromatin remodeling, and the senescence-associated secretory phenotype (SASP). To create these molecular tools to manipulate JMJD3 activity levels, we used functional wild-type and single point mutated Tumor cells were stained with Alexa488-conjugated phalloidin to visualize cell morphology and F-actin filaments. In JMJD3-overexpressing U251 (U251.JMJD3wt; Figure 3B1 , B2) and U87 (U87.JMJD3wt; Figure 3C , D1, D2) glioma cells, cortical F-actin filaments were prominently associated with the plasma membrane, and these cells displayed fewer cell-cell contacts. In contrast, cultures of U251.vector, U251.JMJD3mut, U87.parental, and U87.JMJD3mut cells with lower levels of JMJD3 expression had networks of cell-cell contacts, and phalloidin staining was more evenly distributed throughout their cytoplasm.
ii. Senescence-associated β-galactosidase (SA-β-gal) activity. 
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In parental glioma cell lines we observed higher SA-β-gal activity (as indicated by blue Xgal staining) in U87 than in U251 cells ( Figure 4A 
iii. Proliferation
The tumor suppressor p16, encoded by the INK4a locus, is regulated by the methylation status of H3K27 under specific control by polycomb group proteins (42) (43) (44) . In fibroblasts, recruitment of JMJD3 to the INK4a locus leads to expression of p16, which in turn results in the growth arrest observed during normal cellular senescence(1,15).
U251.JMJD3wt cells displayed changes in cell growth characteristics that were consistent with, but not as complete as, the G1 arrest seen with cellular senescence in non-tumor cells. Rather, while SA-β-gal+ U251.JMJD3wt cells were mitotically active and could be cultured through multiple passages, we observed differences in cell proliferation rates --increase for U251.JMJD3mut and decrease for U251.JMJD3wt cells --when compared to control U251.vector cells ( Figure 4C ). These data suggest that JMJD3 is modulating proliferation of U251 cells, with over-expression (U251.JMJD3wt) slowing, and the inactive form (U251.JMJ3mut) being permissive, for cell division.
iv.
Chromatin remodeling and loss of nuclear envelope integrity.
We next looked at whether JMJD3 expression in U251 cells was related to nuclear morphology [a phenotype that may not be linked to demethylase activity (41)], because chromatin organization can influence the size and shape of nuclear structures (45,46).
We thus examined nuclear architecture and morphology of JMJD3 over-expressing S1A2 ). More detailed examination using transmission electron microscopy ( Figure S1B) and confocal microscopy Z-stack reconstruction ( Figure S1C) showed that the nuclear envelopes of U251.JMJD3wt cells had ruffled architectures suggesting compromise of membrane integrity (arrows in Figure S1A , S1B, S1C) (47) while nuclear envelopes of U251.vector and U251.JMJD3mut cells were smoother.
v. Senescence-associated secretory phenotype (SASP).
The SASP defines a set of genes encoding soluble factors associated with inflammation and also with malignancy (11, (48) (49) (50) . We used a cytokine antibody array to determine differential secretion profiles relative to control U251.vector cells for U251.JMJD3wt and U251.JMJD3mut cells, as well as for U251.JMJD3wt cells exposed to the JMJD3 inhibitor GSK-J4 (30) (which blocks JMJD3-induced H3K27me3 demethylation activity; Figure 2D ).
Of the 78 secreted factors analyzed ( Figure 5A ), U251.JMJD3wt cells secreted higher Figure 5D ).
To better understand JMJD3 targeting of IL-6 and IL-8 genes, we performed a chromatin immunoprecipitation (ChIP) assay to determine whether JMJD3 over-expression reduces H3K27me3 levels specifically at these gene loci. We analyzed CpG islands and transcription factor-binding regions that have been previously reported to have regulatory roles in IL-6 and IL-8 expression (53,54) ( Figure 6B1 ). In U251.JMJD3wt cells, we detected significantly lower levels of H3K27me3 at these sites, compared to U251.vector and U251.JMJD3mut cells, suggesting that these regions are specific targets for JMJD3 ( Figure 6B2 ). These findings suggest that the methylation status of H3K27 determines the expression of IL-6 and IL-8.
iv.
Independence from DNA damage. 
Pathway analysis
We studied the potential of JMJD3 as a global regulator of gene expression by using RNA-seq to examine the expression profile of JMJD3 over-expressing cells (U251.JMJD3wt) relative to vector-only controls. Over-expression of JMJD3 mRNA in U251.JMJD3 cells was confirmed by RT-qPCR ( Figure 2B1 ).
Expression ratio values for the 20,661 genes affected by JMJD3 over-expression in U251 cells are given in Table S1 and plotted in Figure 7 . Of these, 4027 with p < 0.05 are above the horizontal line provided for reference in Figure 7 . IPA (Ingenuity Pathway Analysis) was then used to assess the potential functional impact of the genes affected by JMJD3 over-expression, and associated these changes with two diseases and disorders relevant to this study: 516 genes to "Cancer" (511 with p < 0.05) and 110 genes to "Inflammatory Response" (10 with p < 0.05). The 73 genes common to "Cancer" and "Inflammatory Response" by IPA are also indicated in Figure 7 (72 with p < 0.5) (Table S2 ). Overall, 547 of 4027 genes with p < 0.05 (13.6%) were "Cancer"-and/or "Inflammatory Response"-related, and, with three exceptions, all showed enhanced expression in U251.JMJD3 glioma cells.
Functional assays i. Expression by HB1.F3.NSCs of receptors for cytokines present in the SASP
phenotype.
The SASP cytokine expression signature includes inflammatory cytokines that have been shown in other studies to promote HB1.F3.CD NSC migration (37, 56) . We therefore next 
ii. U251 glioma cell invasion.
Because JMJD3 expression has been associated with enhanced migration (57), we tested the invasiveness of U251.JMJD3wt, compared to U251.vector and U251.JMJD3mut cells using a Matrigel Boyden chamber invasion assay. U251.JMJD3wt cells were significantly more invasive than U251.vector and U251.JMJD3mut cells ( Figure 9A ), suggesting enhanced responsiveness to chemoattractants.
iii.
Migration of NSCs to media conditioned by glioma cells varying in JMJD3
expression. We then used media conditioned by glioma cell lines varying in JMJD3 expression to test whether soluble factors linked to JMJD3 promoted HB1.F3.CD migration in an in vitro Boyden-chamber cell migration assay. As illustrated in Figure 9B1 , HB1.F3.CD migration was greater towards media conditioned by U251.JMJD3wt cells as compared to BSA and U251.vector controls. HB1.F3.CD cell migration towards U251.JMJD3wt conditioned media was also comparable to that seen with media conditioned by U87.parental cells, consistent with their higher basal levels of JMJD3 expression. Enhanced migration associated with JMJD3 over-expression was not limited to NSCs; a similar pattern was observed for mesenchymal stem cells (hTert/MSC) ( Figure 9B2 ).
iv. Comparison of media conditioned by parental U251 and U87 tumor cells.
Prompted by the association of JMJD3 with IL-6 expression in patient samples ( Figure   1B ) and its association with JMJD3wt over-expression in cytokine arrays ( We suggest that JMJD3 activity in cancer may be related to the activation of senescencelike programs overlapping with wound repair and with regeneration. Previous work in zebra fish and mice has shown that JMJD3 is necessary for tissue regeneration (68, 69) .
Epigenetic control over gene expression programs is fundamental to wound healing, and tumors have been described as "wounds that do not heal" since many of the characteristics of cancer overlap with wound healing and chronic inflammation (70) . For example, both wound healing and tumorigenesis induce cell proliferation, angiogenesis and extracellular remodeling, and up-regulate the expression and secretion of select soluble factors directing host cell migration and recruiting tissue specific stem cells for repair (71) .
In concordance with the results from this study, JMJD3 has been shown to regulate expression of IL-6 in mice (3). Linkage of JMJD3 to inflammation is provided by association with stimulation of NF-B pathway expression in macrophages, as M2 macrophage genes are epigenetically regulated by the methylation status of H3K27 (72) .
Upon LPS treatment, JMJD3 has been shown to directly promote inflammatory cytokine production by demethylation of H3K27 at the promoter regions of inflammatory cytokine genes (3,14) (see Figure 9) . A similar aberrant stimulation of canonical pathways might also be controlled by JMJD3 in cancer. Epigenetic stimulation of the NF-B pathway is a mechanism of cancer-related chronic inflammation (73) (Table S1 ). Shown are the ratio (log 2 ) in expression of these 20, 661 genes plotted against p-value (log 10 ). The horizontal line for p = 0.05 is provided for reference. By IPA analysis 516 of these genes were associated with "Cancer" (purple), 511 with p < 0.05 (p = 1.90 x 10 -7 to 0.02), and 110 genes with "Inflammatory response"
(green), 109 with p < 0.05 (p = 1.90 x 10 -7 to 0.02). Seventy three genes were common to "Cancer" and "Inflammatory response" (red), 72 with p < 0.05. Of 4027 genes with p < 0.05, 547 (13.6%) were "Cancer"-and/or "Inflammatory response"-related, and with three exceptions showed enhanced expression in U251.JMJD3 glioma cells. A B 
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